6,000-10,000 total GCC gMG patients is the authoritative epidemiology base; 200-300 refractory patients, fewer than 50 on a biologic today, is the actionable sub-segment inside it, not a second, competing total.
The disease-landscape estimate of 6,000-10,000 GCC gMG patients, roughly 14-20 per 100,000, is built from Al-Shubaili's GCC MG case series and the KFSH&RC neurology database, and this model treats it as the authoritative total prevalence base, the figure a long-run epidemiology forecast should anchor to. It carries its own diagnostic caveat: an estimated 30-40% of GCC gMG patients are initially misdiagnosed as thyroid myopathy given the region's high background thyroid-disease prevalence, so even this base figure understates true prevalence somewhat rather than overstating it.
Inside that base, a launch-readiness assessment sizes the refractory, immunosuppressant-inadequate sub-population at 200-300 patients, of whom fewer than 50 are currently treated with a biologic (efgartigimod or, rarely, eculizumab). This is not a second, competing estimate of the same total; it is a narrower clinical and commercial segment nested inside the 6,000-10,000-patient base, defined by treatment failure rather than by a different counting method. The two figures answer different questions: the epidemiology base sizes the disease, the refractory sub-segment sizes the near-term addressable market for a novel biologic, concentrated at just 10-15 named neuromuscular neurologists across the region who manage nearly all of it.
GCC gMG sizing — a nested refractory segment inside the authoritative prevalence base
| Sizing Layer | Population | Scope | Source |
|---|---|---|---|
| Total prevalence (authoritative base) | 6,000-10,000 patients | All confirmed and estimated GCC gMG, 14-20 per 100,000 | Al-Shubaili GCC MG case series; KFSH&RC neurology database |
| Refractory sub-segment (nested) | 200-300 patients | Immunosuppressant-inadequate, candidates for a novel biologic | GCC neurology society gMG working group; KFSH&RC neuromuscular case series |
| Currently on a biologic (nested further) | Fewer than 50 patients | Efgartigimod or eculizumab, within the refractory sub-segment | argenx GCC access data 2024 |
Sources: Al-Shubaili AF, Eur Neurol 2012; KFSH&RC neurology database 2019-2023; GCC neurology society gMG working group; argenx GCC access data 2024.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- 6,000-10,000-patient disease-landscape prevalence estimate and its case-series sourcing
- the 30-40% thyroid-misdiagnosis confounder
- why this base is treated as a floor, not a ceiling
Delivers
- The refractory, immunosuppressant-inadequate population nested inside the epidemiology base
- the fewer-than-50-patient on-biologic count
- the scope relationship explained explicitly rather than presented as two disagreeing totals
Delivers
- The 10-15-neurologist specialist concentration managing nearly all confirmed GCC refractory gMG
- the commercial-reachability implication of a small, identifiable KOL set
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the refractory sub-segment is nested inside, not competing with, the total prevalence base
- Pressure-tested against the thyroid-myopathy misdiagnosis confounder
- 6,000-10,000-patient GCC gMG prevalence (14-20 per 100,000)
- Why the 30-40% misdiagnosis rate means this base likely understates true prevalence
- 200-300-patient refractory (immunosuppressant-inadequate) sub-segment
- Fewer-than-50-patient current on-biologic count
- Why the two figures answer different questions rather than disagreeing
- The specialist-concentration lens (10-15 neurologists) on commercial reachability
- Which assumption moves the addressable refractory population most
- Misdiagnosis-correction scenario ranges
- The full nested model, re-runnable with your own assumptions
- The open sizing questions your team must close before the number is used in planning
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx market sizing model triangulates at least two independent methods before accepting a patient count. Where a sub-segment estimate is nested inside a broader epidemiology base rather than a competing measurement of the same total, the model states that relationship explicitly rather than treating the two as disagreeing figures.
GCC myasthenia gravis sizing sources: Al-Shubaili AF, Eur Neurol 2012; KFSH&RC neurology database 2019-2023; GCC neurology society gMG working group; and argenx GCC access data 2024.
- Total GCC gMG prevalence and thyroid-misdiagnosis rate verified against Al-Shubaili AF, Eur Neurol 2012 and the KFSH&RC neurology database
- Refractory sub-segment sizing verified against the GCC neurology society gMG working group and KFSH&RC neuromuscular case series
- Current on-biologic count verified against argenx GCC access data 2024
- The nested (not competing) scope relationship between the total base and the refractory sub-segment is stated explicitly, not silently reconciled
Frequently asked questions
Commission this model
AXLRx delivers rare disease market sizing models built for forecasting and strategy teams sizing the GCC gMG opportunity. Custom model in 72 hours.
Specify your indication, target market, and cohort definition.
AXLRx analyst confirms triangulation methods and scope definitions before building.
Research-verified sizing model in 72 hours with optional analyst readout.